AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 41 min read$IRMD

Scharen-Guivel Hilda Frederique sold $285K of IRMD

Scharen-Guivel Hilda Frederique sold 3,000 shares of IRADIMED CORP (IRMD) at $95.00 ($0.28M total) across 2 trades on 2026-06-04.

Original reporting
SEC EDGAR · Scharen-Guivel Hilda Frederique
Published Jun 4, 2026, 8:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRMD
Neutral
medium confidence
Mentioned
$IRMD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRMDNeutralLow
01

Why it matters

The disclosed sale is modest in size relative to the insider's holdings and likely has limited market impact.

02

Market read

A routine insider sale with minimal price effect; useful for tracking insider activity but not a strong trading signal.

03

What to watch

Potential upcoming corporate actions or market conditions that may affect insider behavior.

Relevance 4/10Novelty 4/10Timing: today (filing date)

Background

SEC Form 4 filing discloses an insider transaction by a director of IradiMed Corp.

Company-level read

Ticker impact

$IRMDNeutralMedium confidence
Context

Director Scharen-Guivel Hilda Frederique sold 3,000 shares for $285,000 on 2026-06-04.

Expected impact

likely slight downward pressure as market absorbs the sale

Evidence & confidence

Director sales of this size are routine and typically have limited impact, but can signal minor concern.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

The sale could be a routine liquidity move and not indicative of future performance.

Key entities

  • company
    IradiMed Corp

    Biopharmaceutical company listed on Nasdaq under ticker IRMD.

  • person
    Scharen-Guivel Hilda Frederique

    Director of IradiMed Corp who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRMD insider trading history →

Related articles

AUG 8
$IRMDMedAI 9/10

IRadimed (IRMD) Q2 2026 Earnings Call Transcript

IRadimed (IRMD) reported Q2 2026 revenue of $20.5 million, up 0.5% from $20.4 million a year earlier. GAAP diluted EPS was $0.41 versus $0.45, and non-GAAP EPS was $0.46. Gross margin fell to 74% from 78% due to higher manufacturing costs during the 3870 pump ramp. Q3 revenue guidance is $23.0 to $24.5 million; full-year 2026 revenue guidance is $91 to $96 million.

fool.com7 min
MAY 29
$IRMDMedAI 9/10

Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report

Iradimed Corp (IRMD) reported Q1 2026 results on May 1. The company said revenue rose 13% year over year to $22 million and net income increased 24% to $5.8 million, or $0.45 per share. Iradimed also launched its next-generation 3870 MRI-compatible IV infusion pump in Q1, with shipments expected to begin in Q2. For Q2, it forecast revenue of $20–$21 million and GAAP EPS of $0.40–$0.44; full-year 2026 revenue of $91–$96 million and GAAP EPS of $1.90–$2.05.

finance.yahoo.com4 min
OCT 22
$DOLELow

Pale Fire Capital SE (Senkypl Dusan, Barta Jan) purchased $8.6M of DOLE (indirect holdings)

Pale Fire Capital SE purchased 648,356 indirectly-held shares of Dole plc (DOLE) at an average of $13.19 ($13.12–$13.39, $8.55M total) across 3 trades over 2026-10-20 to 2026-10-22. Filed jointly with Pale Fire Capital SICAV a.s. (10% owner), Pale Fire Capital investicni spolecnost a.s. (10% owner), Senkypl Dusan (10% owner) and Barta Jan (10% owner).

SEC EDGAR1 min